# Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

> **NCT04774926** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 122 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Brolucizumab

## Key facts

- **NCT ID:** NCT04774926
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-15
- **Primary completion:** 2023-10-04
- **Final completion:** 2023-10-04
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04774926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04774926, "Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04774926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*